- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00361595
Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women
Open Label Proof of Concept Study of IV Zoledronic Acid (ZA) 5 mg After Forteo in Postmenopausal Women
연구 개요
상세 설명
This will be a single center open label proof of concept study, recruiting subjects previously treated with Forteo for at least 12 months.
A screening period of 3 to 6 weeks will precede the treatment period. At the baseline visit, patients whose eligibility is confirmed will be treated with ZA and followed for 12 months. Safety and efficacy will be assessed at regular intervals (day one, day 10, month 2, month 6, month 9 and month 12). Renal safety will be assessed prior to the i.v. dose of study medication, day 10 after the i.v. dose of study medication and at 12 months. Bone density at the lumbar spine (L1-4) and total hip will be performed at 6 months and at the end of the 12 month treatment period. Biomarker analyses for secondary endpoint will be performed for at day 10, month 2, month 6, month 9 and month 12.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Ohio
-
Cleveland, Ohio, 미국, 44195
- The Cleveland Clinic Foundation
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Postmenopausal women to age 85, inclusive
- Finish treatment of 12 months or longer with Forteo
- Signed informed consent prior to initiation of any study-mandated procedure.
Exclusion Criteria:
- Hip and spine DXA T-score >-1.0
- Patients with 25-(OH) vitamin D levels less than 15 ng/mL at Visit 1. (Patient can be repleted with vitamin D 50,000 units biweekly for up to 2 months and re-screened anytime during the 2 months while continuing Forteo.)
- Baseline renal insufficiency (calculated creatinine clearance less than 40.0 mL/min (MDRD) at Visit 1 and/or Visit 2 or urine dipstick greater than or equal to 2+ protein without evidence of contamination or bacteriuria (may be repeated one time at least a week apart if there is suspicion of contamination). Patients with calculated creatinine clearance equal to or greater than 40.0 mL/min and less than 60.0 mL/min or serum creatinine greater than the upper limit of normal at Visit 1 must be retested between Visit 1 and 2. Patients with calculated creatinine clearance greater than 60.0 mL/min and serum creatinine within normal limits at Visit 1 do not require re-test.
- Patients who require re-test of creatinine clearance between Visit 1 and 2 will be excluded if there is an increase in serum creatinine greater than 0.5 mg/dL between Visit 1 and Visit 2.
- Serum calcium <8.5 or >11.0 mg/dl at Visit 1
- AST or ALT greater than twice the upper limit of normal
- Serum alkaline phosphatase greater than 1.5 times the upper limit of normal (liver fraction)
- No history of retinopathy or nephropathy especially in the presence of uncontrollable IDDM with Hb1 AC > 10%
- Hypersensitivity to bisphosphonates
- Treatment with biphosphonates while on Forteo
- Prior treatment with i.v. biphosphonates
- Estrogen, calcitonin, raloxifene use prior to Forteo treatment are not exclusions, but concomitant therapy during with any bone agents during the trial will not be permitted
- Any prior use of strontium ranelate or sodium fluoride
- Chronic use of systemic corticosteroids (oral or i.v.) within the last year:
NOTE: Use of corticosteroids in forms such as topical creams, nasal or inhaled formulations or those injected locally (intra-articularly) are NOT exclusionary.
- Prior exposure to anabolic steroids or growth hormone within 6 months prior to randomization
- Treatment with any investigational drug(s) and/or devices within 30 days prior to randomization.
- History of iritis or uveitis, except when secondary to trauma, and must have resolved for more than 2 years prior to randomization.
Cancer exclusions:
- Patients with a new diagnosis or active treatment for any malignancy less than or equal to 12 months prior to Visit 1.
- Patients with evidence of any metastases on or prior to randomization, or with a history of metastases
- Subjects with evidence of paraneoplastic syndrome, especially those characterized by hypercalcemia during screening or by history
- Patients with the following may be included: basal cell or squamous cell carcinoma of the skin, colonic polyps with non-invasive malignancy which have been removed, and Carcinoma in-situ (CIS) of the prostate (Stage I only) that has been surgically removed.
- Previous major solid organ or bone marrow transplant recipient or on a transplant waiting list
- Any disease of the spine that would preclude the proper acquisition of a lumbar spine DXA (L1-L4) e.g., implantable devices, scoliosis, ankylosing spondylitis, DJD. (Less than two lumbar spine vertebral bodies evaluable)
- Active primary hyperparathyroidism or hypoparathyroidism
- Subject with complete thyroidectomy
- Active hyperthyroidism
- Hypothyroidism not treated with adequate replacement therapy
- History of multiple myeloma or Paget's disease
- Patients with severe dental problems or current dental infections, or with recent or impending dental surgery within three months of dosing
- Any medical or psychiatric condition which, in the opinion of the investigator, would preclude the participant from adhering to the protocol or completing the trial per protocol
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: open label
5 mg zoledronic acid in a single 15 minute IV
|
5 mg zoledronic acid administered in a single 15 minute IV
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Change in Lumbar Spine BMD (Bone Mineral Density) in g/cm^2 From Baseline to Month 12 Relative to Baseline as Measured by DXA (Dual-energy X-ray Absorptiometry)
기간: Baseline and 12 months
|
Baseline and 12 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Change in Bone Density (Grams/cm^2) at the Total Hip at 6 and 12 Months
기간: 6 months and 12 months
|
Change in bone density (grams/cm^2) at the total hip at 6 and 12 months.
12 month reported based on usual interval for bone density follow-up in clinical practice.
|
6 months and 12 months
|
Change in Serum C-telopeptide Type 1 Collagen (CTX) (at Day 10 and Months 2, 6, 9 and 12)
기간: 12 months
|
Change in serum c-telopeptide type 1 collagen (CTX) (at day 10 and months 2, 6, 9 and 12. 12 month values reported based on 12 month duraton of zolendronic acid effect.
|
12 months
|
Change in Serum N-propeptide Type 1 Collagen (P1NP) (at Day 10 and Months 2, 6, 9 and 12)
기간: 12 months
|
Change in serum n-propeptide type 1 collagen (P1NP) (at day 10 and months 2, 6, 9 and 12. 12 month values reported based on 12 month duraton of zolendronic acid effect.
|
12 months
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Chad Deal, MD, The Cleveland Clinic
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
zoledronic acid에 대한 임상 시험
-
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...완전한
-
National University of Ireland, Galway, IrelandStanley Medical Research Institute완전한
-
Daewoong Pharmaceutical Co. LTD.완전한
-
University Hospital, Akershus모병
-
University Hospital, Basel, Switzerland완전한
-
University College, LondonImperial College London; Cancer Research UK; National Cancer Imaging Translational Accelerator모병
-
Massachusetts General Hospital완전한